Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,992.80
(
0.47%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.71
(
1.14%
)
Bitcoin
76,533.93
(
0.85%
)
News Focus
News Focus
Post# of 822149
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

AAPL31415926

Send PM Follow Ignore
Followers 8
Posts 309
Boards Moderated 0
Alias Born 05/19/2022

AAPL31415926

Re: skitahoe post# 756007

Sunday, 03/23/2025 10:42:43 PM

Sunday, March 23, 2025 10:42:43 PM

Post# of 822149
Gary don't sell the company short. Merck gets $25 billion per year revenue from Keytruda. I think they'd be happy to pay $25B for Nwbo to extend their patent out another 10 years and prevent anyone else from having this treatment. Not to mention all the patents and Flaskworks. And that would probably equal at least $15 per share which I think most would be happy with.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News